<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333046</url>
  </required_header>
  <id_info>
    <org_study_id>H-27471-TACTAL</org_study_id>
    <secondary_id>TACTAL</secondary_id>
    <secondary_id>2P50CA126752-11</secondary_id>
    <nct_id>NCT01333046</nct_id>
    <nct_alias>NCT01556269</nct_alias>
  </id_info>
  <brief_title>Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL</brief_title>
  <acronym>TACTAL</acronym>
  <official_title>Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active or Relapsed Hodgkin or Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Cell and Gene Therapy, Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients have a type of lymph gland disease called Hodgkin or non-Hodgkin lymphoma which has&#xD;
      come back, or may come back, or has not gone away after treatment, including the standard&#xD;
      treatment known for these diseases. This a research study using special immune system cells&#xD;
      called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes, a new experimental&#xD;
      therapy.&#xD;
&#xD;
      This sort of therapy has been used previously to treat Hodgkin or non-Hodgkin lymphomas that&#xD;
      show proof of infection with Epstein-Barr virus (EBV), the virus that causes infectious&#xD;
      mononucleosis (&quot;mono&quot; or the &quot;kissing disease&quot;). EBV is found in cancer cells of up to half&#xD;
      of all patients with Hodgkin's and non-Hodgkin lymphoma. This suggests that it may play a&#xD;
      role in causing lymphoma. The cancer cells infected by EBV are able to hide from the body's&#xD;
      immune system and escape being killed. Investigators tested whether special white blood&#xD;
      cells, called T cells, that were trained to kill EBV-infected cells could affect these&#xD;
      tumors, and in many patients it was found that giving these trained T cells caused a complete&#xD;
      or partial response.&#xD;
&#xD;
      However, many patients do not have EBV in their lymphoma cells; therefore investigators now&#xD;
      want to test whether it is possible to direct these special T cells against other types of&#xD;
      proteins on the tumor cell surface with similar promising results. The proteins that will be&#xD;
      targeted in this study are called tumor associated antigens (TAAs) - these are cell proteins&#xD;
      that are specific to the cancer cell, so they either do not show or show up in low quantities&#xD;
      on normal human cells.&#xD;
&#xD;
      In this study, we will target five TAAs which commonly show on lymphoma, called: NY-ESO-1,&#xD;
      MAGEA4, PRAME, Survivin and SSX. This will be done by using special types of T cells called&#xD;
      cytotoxic T lymphocytes (CTLs) generated in the lab.&#xD;
&#xD;
      In addition, some adult patients will receive a drug called azacytidine before giving the T&#xD;
      cells. We hope that the combination helps the T cells work better.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient will give blood to make TAA-specific cytotoxic T cells in the lab. These cells&#xD;
      will be grown and frozen. If the TAA-specific cytotoxic T cells can be made, the time from&#xD;
      collection of the blood to manufacture of T cells for administration to the patient is about&#xD;
      1 to 2 months.&#xD;
&#xD;
      There are 4 stages of this study: an antigen-escalation phase, a dose-escalation stage, aza&#xD;
      stage and pediatric patients stage.&#xD;
&#xD;
      The antigen-escalation phase will be first. Patients will receive TAA-specific T cells&#xD;
      targeting first 1 and then 2 TAAs. Once this schedule proves safe, the next group of patients&#xD;
      will receive TAA-specific T cells targeting first 2 and then 3 TAAs. This process will&#xD;
      continue until all 4 levels are studied. This means that the final cohort of patients will&#xD;
      receive TAA-specific T cells targeting first 4 and then 5 TAAs. If the side-effects are too&#xD;
      severe, the number of TAAs being targeted will be lowered or the T cell injections will be&#xD;
      stopped. Each patient will receive 2 infusions at the same dose 28 days apart&#xD;
&#xD;
      After the antigen-escalation phase, the dose-escalation phase will begin. Patients will be&#xD;
      started on the lowest dose (1 of 3 different levels) of T cells. Once that dose schedule&#xD;
      proves safe, the next group of patients will be started at a higher dose. This process will&#xD;
      continue until all 3 dose levels are studied. If the side-effects are too severe, the dose&#xD;
      will be lowered or the T cell injections will be stopped. Each patient will receive 2&#xD;
      infusions at the same dose 14 days apart&#xD;
&#xD;
      After the dose escalation stage, adult patients will be enrolled on the aza stage where they&#xD;
      will receive the drug aza followed by two infusions of T cells on dose level 2. Patients will&#xD;
      be given 3 cycles of aza (administered daily through a vein for 5 days, every 28 days)&#xD;
      followed by 2 doses of multiTAA-specific T cells administered 14 days apart. Before the&#xD;
      patient is given the aza they will be given a drug to help prevent nausea and vomiting.&#xD;
&#xD;
      On the pediatric stage, pediatric patients will receive 2 infusions of T cells on dose level&#xD;
      2. The T cells will be given 14 days apart.&#xD;
&#xD;
      The cells will be injected by IV over 10 minutes. The patients may be pre-treated with&#xD;
      acetaminophen (Tylenol) and diphenhydramine (Benadryl). Acetaminophen (Tylenol) and&#xD;
      diphenhydramine (Benadryl) are given to prevent a possible allergic reaction to the T cell&#xD;
      administration. If after the second infusion there is a reduction in the size of the&#xD;
      patient's lymphoma on CT or MRI scan as assessed by a radiologist, the patient can receive up&#xD;
      to six (6) additional doses of the T cells at monthly intervals if they wish. All of the&#xD;
      treatments will be given by the Center for Cell and Gene Therapy at Houston Methodist&#xD;
      Hospital or Texas Children's Hospital.&#xD;
&#xD;
      In between the first and second T cell infusions and for 6 weeks after the last infusion, the&#xD;
      patient should not receive any other anti-cancer treatments such as radiation therapy or&#xD;
      chemotherapy. If the patient does receive any other therapies in-between the first and second&#xD;
      infusion of T cells, they will be taken off treatment and will not be able to receive the&#xD;
      second infusion of T cells.&#xD;
&#xD;
      MEDICAL TESTS BEFORE TREATMENT&#xD;
&#xD;
        -  Physical exam.&#xD;
&#xD;
        -  Blood tests to measure blood cells, kidney and liver function.&#xD;
&#xD;
        -  Measurements of your tumor by routine imaging studies. We will use the imaging study&#xD;
           that was used before to follow your tumor: CT, MRI, or PET.&#xD;
&#xD;
        -  Pregnancy test if you are a female who can have children.&#xD;
&#xD;
      MEDICAL TESTS AFTER TREATMENT&#xD;
&#xD;
      - Imaging study 6 weeks after the 2nd TAA-CTL infusion.&#xD;
&#xD;
      To learn more about the way the T cells are working in the patient's body, an extra 20-40 mL&#xD;
      (4-8 teaspoons) of blood will be taken before each cycle of aza (if applicable), 2 weeks&#xD;
      after each cycle of aza (if applicable), before each T-cell infusion, and at Weeks 1, 2, 4&#xD;
      and 6. One additional blood sample might be drawn 3 to 4 days post the T-cell infusion; this&#xD;
      is optional. Afterwards, blood will be collected at 3, 6, 9 and 12 months after the last&#xD;
      infusion. The blood may be drawn from a central line at the time of the patient's regular&#xD;
      blood tests. Investigators will use this blood to see how long the T cells last,and to look&#xD;
      at the immune response to the patient's cancer.&#xD;
&#xD;
      Study Duration: Patients will be on active study participation for approximately one year.&#xD;
      Patients who receive additional doses of the T cells as described above will be actively&#xD;
      followed until 1 year after their last dose of T cells. Investigators will then remain in&#xD;
      contact with patients once a year for up to 4 additional years (total of 5 years follow-up)&#xD;
      in order to evaluate disease response long-term.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">May 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of patients with adverse events</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine the safety of 2 intravenous injections of autologous TAA-specific cytotoxic T lymphocytes (CTLs) in patients with Hodgkin or non-Hodgkin lymphoma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with treatment related Serious Adverse Events</measure>
    <time_frame>8 weeks</time_frame>
    <description>To determine whether infusion of TAA-specific T cells targeting multiple tumor antigens in combination with azacytidine is safe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtain information on the expansion, persistence and anti-tumor effects of the adoptively-transferred TAA-specific CTLs</measure>
    <time_frame>1 year</time_frame>
    <description>Information on the expansion, persistence and anti-tumor effects of the adoptively transferred tumor-specific CTLs will be analyzed for the immunological parameters based on multimer analysis, intracellular cytokine staining and ELIspot assays to assess the frequency of cells secreting Î³-IFN using the descriptive statistics such as mean, median, standard deviation at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of increasing the spectrum of epitopes/antigens</measure>
    <time_frame>1 year</time_frame>
    <description>To determine whether CTL infusions increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>Antigen-Escalation Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first stage will be an &quot;antigen-escalation&quot; stage using a fixed total dose of cells (5 x 10^6 cells/m^2 x 2) to evaluate the safety of the T cells primed against PRAME pepmix, and then SSX pepmix, and then MAGE A4 pepmix, and then NY-ESO pepmix, and then SURVIVIN pepmix.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-Escalation Study Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the dose escalation stage, three dose levels will be studied. Patients in the dose escalation portion of the study will be entered and stratified separately to the following two groups:&#xD;
Group A: Patients receiving CTLs as therapy for Hodgkin's or non-Hodgkin's lymphoma.&#xD;
Group B: Patients receiving CTLs as adjunctive therapy following autologous or syngeneic transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azacytidine and multiTAA T cells Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This phase will administer aza intravenously at a dose of 75 mg/m2 after premedication with an anti-emetic such as ondansetron po or IV (up to a maximum dose of 16 mg ondansetron or equivalent). This phase will determine whether infusion of TAA-specific T cells (at dose level 2 - 1x10^7) targeting multiple tumor antigens in combination with azacytidine is safe, and whether CTL infusions (with or without azacytidine) increase the spectrum of epitopes/antigens targeted by endogenous T cells (epitope spreading).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pediatric multiTAA T cells Stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This phase will give patients &lt; 18 years old two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. This phase will test the safety and efficacy of multiTAA-specific T cells in pediatric patients with active HL/NHL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Antigen-Escalation Stage</intervention_name>
    <description>Antigen-Escalation Stage&#xD;
Each patient will receive 2 injections at the same dose (5 x 10^6 cells/m2), 28 days apart, according to the following schedules:&#xD;
Schedule One:&#xD;
Day 0: PRAME-specific T cells&#xD;
Day 28: PRAME- and SSX-specific T cells&#xD;
Schedule Two:&#xD;
Day 0: PRAME- and SSX-specific T cells&#xD;
Day 28: PRAME/SSX/MAGE-specific T cells&#xD;
Schedule Three:&#xD;
Day 0: PRAME/SSX/MAGE-specific T cells&#xD;
Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells&#xD;
Schedule Four:&#xD;
Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells&#xD;
Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells</description>
    <arm_group_label>Antigen-Escalation Stage</arm_group_label>
    <other_name>T cell injection</other_name>
    <other_name>Tumor-specific CTL lines</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Dose-Escalation Stage</intervention_name>
    <description>Dose-Escalation Stage&#xD;
Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:&#xD;
DL1: Day 0 and Day 14: 5 x 10^6 cells/m^2&#xD;
DL2: Day 0 and Day 14: 1 x 10^7 cells/m^2&#xD;
DL3: Day 0 and Day 14: 2 x 10^7 cells/m^2</description>
    <arm_group_label>Dose-Escalation Study Stage</arm_group_label>
    <other_name>TAA-CTL infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>azacytidine and multiTAA T cells Stage</intervention_name>
    <description>Up to 15 patients will be treated with 3 cycles of aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10^7 cells/m2. If drug-related myelosuppression occurs aza dosing will be modified, according to the following:&#xD;
ANC &gt;1,000 or Platelets &gt;50,000 (or any other grade I AE attributable to aza)&#xD;
Adjustment: None&#xD;
ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to aza)&#xD;
Adjustment: 50% dose reduction&#xD;
ANC &lt;500 or any episode of febrile neutropenia or platelets &lt;25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to aza)&#xD;
Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last aza infusion</description>
    <arm_group_label>azacytidine and multiTAA T cells Stage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pediatric multiTAA T cells Stage</intervention_name>
    <description>Patients &lt; 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.</description>
    <arm_group_label>Pediatric multiTAA T cells Stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PROCUREMENT:&#xD;
&#xD;
          1. Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma.&#xD;
&#xD;
          2. Life expectancy of 6 weeks or greater.&#xD;
&#xD;
          3. Hgb greater than or equal to 7.0&#xD;
&#xD;
          4. Patient and,or parent,guardian able to give informed consent.&#xD;
&#xD;
        TREATMENT:&#xD;
&#xD;
          1. Any patient regardless of sex, with a diagnosis of Hodgkin or non-Hodgkin lymphoma:&#xD;
&#xD;
             Group A: Patients greater than or equal to 18 years old&#xD;
&#xD;
               -  with active disease:&#xD;
&#xD;
                    -  in second or subsequent relapse.&#xD;
&#xD;
                    -  in first relapse for indolent lymphoma after first-line therapy for relapse.&#xD;
&#xD;
                    -  or first relapse if immunosuppressive chemotherapy contraindicated.&#xD;
&#xD;
                    -  primary refractory disease or if persistent disease after first-line therapy&#xD;
                       of relapse.&#xD;
&#xD;
               -  or multiply relapsed patients in remission who are at a high risk of relapse.&#xD;
&#xD;
               -  or the lymphoma is a second malignancy e.g. a Richters transformation of CLL&#xD;
                  after failing front line therapy.&#xD;
&#xD;
             OR&#xD;
&#xD;
             Group B: Patients greater than or equal to 18 years old after autologous or syngeneic&#xD;
             SCT (as adjuvant therapy).&#xD;
&#xD;
             OR&#xD;
&#xD;
             Group C: azacytidine plus multiTAA-T cells Patients greater than or equal to 18 years&#xD;
             old&#xD;
&#xD;
               -  with active disease in:&#xD;
&#xD;
                    -  second or subsequent relapse&#xD;
&#xD;
                    -  first relapse for indolent lymphoma after first line therapy for relapse&#xD;
&#xD;
                    -  first relapse if immunosuppressive chemotherapy contraindicated&#xD;
&#xD;
               -  with primary refractory disease or persistent disease after first line therapy of&#xD;
                  relapse&#xD;
&#xD;
               -  or lymphoma as a second malignancy e.g. a Richters transformation of CLL after&#xD;
                  failing front line therapy&#xD;
&#xD;
             OR&#xD;
&#xD;
             GROUP D: Patients less than 18 yrs old&#xD;
&#xD;
               -  with active disease in:&#xD;
&#xD;
                    -  second or subsequent relapse&#xD;
&#xD;
                    -  first relapse for indolent lymphoma after first line therapy for relapse&#xD;
&#xD;
                    -  first relapse if immunosuppressive chemotherapy contraindicated&#xD;
&#xD;
               -  with primary refractory disease or persistent disease after first line therapy of&#xD;
                  relapse&#xD;
&#xD;
               -  with lymphoma as a second malignancy e.g. a Richters transformation of CLL after&#xD;
                  failing front line therapy&#xD;
&#xD;
          2. Life expectancy of 6 weeks or greater.&#xD;
&#xD;
          3. Pulse oximetry of more than 95 percent on room air in patients who previously received&#xD;
             radiation therapy.&#xD;
&#xD;
          4. Karnofsky,Lansky score of 50 or greater.&#xD;
&#xD;
          5. Creatinine 2X or less of upper limit of normal for age.&#xD;
&#xD;
          6. Patients should have been off other investigational therapy for one month prior to&#xD;
             entry in this study.&#xD;
&#xD;
          7. Patients should have been off conventional therapy for at least 1 week prior to entry&#xD;
             in this study, including rituximab.&#xD;
&#xD;
          8. Patient and,or parent,guardian able to give informed consent.&#xD;
&#xD;
          9. Due to unknown effects of this therapy on a fetus, pregnant women are excluded from&#xD;
             this research. The male partner should use a condom. Females of child-bearing&#xD;
             potential should use of at least two forms of contraception unless female has had a&#xD;
             hysterectomy or tubal ligation.&#xD;
&#xD;
         10. Bilirubin 2X or less of upper limit of normal, AST 3X or less than the upper limit of&#xD;
             normal, and Hgb greater than or equal to 7.0&#xD;
&#xD;
             GROUP C (aza) Only:&#xD;
&#xD;
         11. Platelets greater than 25,000&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        PROCUREMENT:&#xD;
&#xD;
          1. Patients with severe intercurrent infection.&#xD;
&#xD;
          2. Patients with active HIV infection at time of procurement (can be pending at the time&#xD;
             of blood draw).&#xD;
&#xD;
          3. Patients receiving systemic corticosteroids.&#xD;
&#xD;
        TREATMENT:&#xD;
&#xD;
          1. Patients with severe intercurrent infection.&#xD;
&#xD;
          2. Patients receiving systemic corticosteroids.&#xD;
&#xD;
          3. Pregnant breastfeeding.&#xD;
&#xD;
          4. Active viral infection with HIV or hepatitis type B or C. &quot;Active&quot; infection defined&#xD;
             as infectious disease testing indicating that patient blood is reactive for Hep B, C&#xD;
             and/or HIV and confirmed using PCR to measure viral load.&#xD;
&#xD;
             GROUP C (aza) Only:&#xD;
&#xD;
          5. Abnormal coagulation parameters (PT greater than 15 seconds, PTT greater than 40&#xD;
             seconds, and/or INR greater than 1.5)&#xD;
&#xD;
          6. Significant active cardiac disease within the previous 6 months including:&#xD;
&#xD;
               1. NYHA class 4 CHF&#xD;
&#xD;
               2. Unstable angina&#xD;
&#xD;
               3. Myocardial infarction&#xD;
&#xD;
          7. Known or suspected hypersensitivity to azacitidine or mannitol&#xD;
&#xD;
          8. Patients with advanced malignant hepatic tumors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoge Carrum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Carrum, MD</last_name>
    <phone>713-441-1450</phone>
    <email>gcarrum@bcm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Callejas</last_name>
    <phone>832-824-1538</phone>
    <email>wlcalle2@texaschildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Carrum, MD</last_name>
      <phone>713-441-1450</phone>
      <email>gcarrum@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Callejas</last_name>
      <phone>832-824-1538</phone>
      <email>wlcalle2@texaschildrens.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Carrum, MD</last_name>
      <phone>713-441-1450</phone>
      <email>gcarrum@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Callejas</last_name>
      <phone>832-824-1538</phone>
      <email>wlcalle2@texaschildrens.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>George Carrum</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non-Hodgkin Lymphoma</keyword>
  <keyword>CTL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

